Abstract
The following describes a patient on a stable regimen of warfarin who developed severe hypoprothrombinemia and bleeding 4 weeks after starting gemfibrozil. Despite a warning by the manufacturer, only one report of this interaction has been published in the literature. This interaction may be overlooked by clinicians, which may result in a serious bleeding risk for patients on warfarin.
MeSH terms
-
Aged
-
Anticoagulants / adverse effects*
-
Drug Interactions
-
Follow-Up Studies
-
Gemfibrozil / adverse effects*
-
Hemorrhage / chemically induced
-
Humans
-
Hyperlipidemias / drug therapy
-
Hypolipidemic Agents / adverse effects*
-
Hypoprothrombinemias / chemically induced*
-
Male
-
Thrombophlebitis / drug therapy
-
Warfarin / adverse effects*
Substances
-
Anticoagulants
-
Hypolipidemic Agents
-
Warfarin
-
Gemfibrozil